VKTX has been the topic of several other reports. HC Wainwright set a $31.00 price objective on shares of Viking Therapeutics and gave the company a buy rating in a research report on Monday, October 1st. SunTrust Banks initiated coverage on shares of Viking Therapeutics in a research report on Friday, July 20th. They issued a buy rating and a $14.00 price objective on the stock. Raymond James set a $43.00 price objective on shares of Viking Therapeutics and gave the company a buy rating in a research report on Wednesday, September 19th. BidaskClub raised shares of Viking Therapeutics from a hold rating to a buy rating in a research report on Saturday, July 21st. Finally, William Blair reaffirmed an outperform rating on shares of Viking Therapeutics in a research report on Friday, August 10th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of Buy and an average target price of $28.00.
VKTX traded down $0.81 during trading on Friday, hitting $12.33. The company had a trading volume of 4,027,446 shares, compared to its average volume of 2,957,749. The stock has a market capitalization of $851.64 million, a P/E ratio of -15.61 and a beta of 2.92. Viking Therapeutics has a one year low of $2.24 and a one year high of $24.00.
Viking Therapeutics (NASDAQ:VKTX) last posted its quarterly earnings data on Friday, November 9th. The biotechnology company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.01. As a group, equities research analysts predict that Viking Therapeutics will post -0.44 EPS for the current fiscal year.
In other Viking Therapeutics news, major shareholder Ligand Pharmaceuticals Inc sold 262,881 shares of the business’s stock in a transaction dated Tuesday, September 25th. The shares were sold at an average price of $19.15, for a total transaction of $5,034,171.15. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 3.90% of the company’s stock.
A number of large investors have recently modified their holdings of the business. FMR LLC bought a new stake in Viking Therapeutics during the 3rd quarter worth about $125,858,000. Boxer Capital LLC lifted its position in Viking Therapeutics by 17.7% during the 2nd quarter. Boxer Capital LLC now owns 3,750,000 shares of the biotechnology company’s stock worth $35,588,000 after buying an additional 564,000 shares in the last quarter. BlackRock Inc. lifted its position in Viking Therapeutics by 14.0% during the 3rd quarter. BlackRock Inc. now owns 3,349,901 shares of the biotechnology company’s stock worth $58,355,000 after buying an additional 411,256 shares in the last quarter. Janus Henderson Group PLC bought a new stake in Viking Therapeutics during the 2nd quarter worth about $19,552,000. Finally, Millennium Management LLC lifted its position in Viking Therapeutics by 99.1% during the 1st quarter. Millennium Management LLC now owns 1,399,370 shares of the biotechnology company’s stock worth $6,115,000 after buying an additional 696,398 shares in the last quarter. 53.56% of the stock is currently owned by hedge funds and other institutional investors.
About Viking Therapeutics
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.
See Also: Bond
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.